Literature DB >> 26481415

Xeno-immunosuppressive properties of human decidual stromal cells in mouse models of alloreactivity in vitro and in vivo.

Behnam Sadeghi1, Yaser Heshmati2, Bita Khoein3, Helen Kaipe3, Mehmet Uzunel3, Julian Walfridsson2, Olle Ringdén4.   

Abstract

BACKGROUND AIMS: Human decidual stromal cells (hDSCs) may cure acute graft-versus-host disease (GVHD) in humans. We evaluated immunosuppression by xenogenic hDSCs in mice, both in vitro and in vivo.
METHODS: hDSCs inhibited mouse lymphocyte proliferation in allo- and xeno-stimulation assays in mixed lymphocyte culture (MLC) and after mitogenic stimulation. The immunosuppressive effect of hDSCs was dose-dependent and strain-independent. Trans-well experiments showed that hDSCs needed cell-to-cell contact to be immunosuppressive. In a GVHD model, Balb/c mice were transplanted with bone marrow and splenocytes from C57BL/6 a donor. Varying doses of hDSCs (10(5)-10(6) per mouse) were infused at different time points. Recipient mice showed lower GVHD scores than untreated mice, but they did not have consistently improved survival. Histopathological investigation of liver, gastrointestinal tract and skin of animals with GVHD did not show any significant improvement from hDSC infusion.
RESULTS: hDSCs were transduced with immunosuppressive genes including those encoding interleukin-10, prostaglandin-E2 receptor, indoleamine dioxygenase, interferon-γ and programmed death ligand-1. Transduced and untransduced hDSCs showed similar effects in vitro and in vivo. At a dose of 10(6)hDSCs per mouse, the majority of recipients died of embolism.
CONCLUSIONS: hDSCs inhibit allo-reactivity, xeno-reactivity and mitogen-induced stimulation in mouse lymphocytes. Although the GVHD score was reduced by hDSC infusion, survival and GVHD histopathology were not improved. One reason for failure was fatal embolism.
Copyright © 2015 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cell therapy; decidual stromal cells; graft-versus-host disease; mesenchymal stromal cells; mouse model

Mesh:

Substances:

Year:  2015        PMID: 26481415     DOI: 10.1016/j.jcyt.2015.09.001

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  8 in total

1.  Cytotrophoblasts suppress macrophage-mediated inflammation through a contact-dependent mechanism.

Authors:  Alison J Eastman; Erin N Vrana; Maria T Grimaldo; Amanda D Jones; Lisa M Rogers; Donald J Alcendor; David M Aronoff
Journal:  Am J Reprod Immunol       Date:  2020-10-16       Impact factor: 3.886

2.  The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review.

Authors:  Alessander Leyendecker; Carla Cristina Gomes Pinheiro; Mariane Tami Amano; Daniela Franco Bueno
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

3.  Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model.

Authors:  Céline Grégoire; Caroline Ritacco; Muriel Hannon; Laurence Seidel; Loïc Delens; Ludovic Belle; Sophie Dubois; Sophie Vériter; Chantal Lechanteur; Alexandra Briquet; Sophie Servais; Gregory Ehx; Yves Beguin; Frédéric Baron
Journal:  Front Immunol       Date:  2019-04-02       Impact factor: 7.561

4.  Human predecidual stromal cells are mesenchymal stromal/stem cells and have a therapeutic effect in an immune-based mouse model of recurrent spontaneous abortion.

Authors:  Raquel Muñoz-Fernández; Claudia De La Mata; Francisco Requena; Francisco Martín; Pablo Fernandez-Rubio; Tatiana Llorca; Maria José Ruiz-Magaña; Carmen Ruiz-Ruiz; Enrique G Olivares
Journal:  Stem Cell Res Ther       Date:  2019-06-14       Impact factor: 6.832

5.  Preclinical Toxicity Evaluation of Clinical Grade Placenta-Derived Decidua Stromal Cells.

Authors:  Behnam Sadeghi; Gianluca Moretti; Fabian Arnberg; Erik Samén; Bita Kohein; Rusan Catar; Julian Kamhieh-Milz; Sven Geissler; Guido Moll; Staffan Holmin; Olle Ringdén
Journal:  Front Immunol       Date:  2019-11-19       Impact factor: 7.561

6.  Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.

Authors:  Olle Ringdén; Guido Moll; Britt Gustafsson; Behnam Sadeghi
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

7.  Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: A meta-analysis of animal models.

Authors:  Li Wang; Haiyan Zhang; Lixun Guan; Shasha Zhao; Zhenyang Gu; Huaping Wei; Zhe Gao; Feiyan Wang; Nan Yang; Lan Luo; Yonghui Li; Lili Wang; Daihong Liu; Chunji Gao
Journal:  Oncotarget       Date:  2016-09-20

8.  The histone chaperone NAP1L3 is required for haematopoietic stem cell maintenance and differentiation.

Authors:  Yaser Heshmati; Shabnam Kharazi; Gözde Türköz; David Chang; Esmat Kamali Dolatabadi; Johan Boström; Aleksandra Krstic; Theodora Boukoura; Emma Wagner; Nadir Kadri; Robert Månsson; Mikael Altun; Hong Qian; Julian Walfridsson
Journal:  Sci Rep       Date:  2018-07-25       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.